Science recently learned —50% of medications work through GPCR signaling. But, 99% of existing drugs were discovered by luck: trial, error, observation and testing, over years. The ability to produce stable water-soluble protein replicants is a fundamental new tool that opens many doors: Drug Discovery Our technology provides a critical revitalization of drying pharma pipelines: (i) Addresses compounds with poor solubili- ty (over 40% of drugs) offering increased efficacy and faster, cheaper development. (ii) Enables novel drug candidates for GPCR-mediated diseases: *Examples include: Alzheimer's (GPR3) Parkinson's (GPCR 37) Prostate cancer (GPR68/0GR I) Arteriosclerosis (GPRS 176) Asthma (CCR3.CXCR2) Cancer metastasis (CXCR4) Colon cancer (MASI) Ovarian Cancer (OCR I) Leukemia (P2Y8/P2 R Y8) Diabetes (GPCR 21) Autism (GPCR 63) Bipolar disorder (GPRS 78) Osteoarthritis (GPR22) Lung cancer (GPR87) Breast Cancer (CXCR4) (Plus over 700 others and the list grows almost daily.) Research Tools - Provide our synthetic GPCRQTY materials, duplicating native GPCR functionality in a water-soluble form to research laboratories. Diagnostics - Water-soluble GPCRQTY materials maintain ligand binding ability to specific antigens/receptors, providing a new class of novel, low-cost diagnostics. mAB-Similar Products - New molecular therapeutics: (i) Target-designed to be similar to monoclonal antibodies, but easier to produce; (ii) Engineering mAbQTY to reduce mAb aggregation and increase long-term storage. Autoimmune/Allergy Therapy - Use GPCRQTY as decoy treat- ment (similar to Enbrel/Etanercept), theoretically for any disease or condition associated with GPCR signaling. Viral Therapeutics - Use Receptors QTY to trap viruses including: HIV, Ebola, Marburg & Lassa - for rapid reduction of viral loads. Molecular Sensors - Use Receptors QTY to create ultra-sensitive bionic detectors. (e.g. a chip-based bionic nose.) Imagine a world in which we